Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims in relation to gamma-linolenic acid and maintenance of normal blood LDL-cholesterol concentrations, maintenance of normal blood pressure, reduction of menstrual discomfort, contribution to normal cognitive function, maintenance of the barrier function of the skin, ―function of the cell membrane‖, maintenance of normal structure, elasticity and appearance of the skin, and ―anti-inflammatory properties‖. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders. The food constituents that are the subject of the health claims are ―gamma-linolenic acid (GLA; C18: 3n-6) provided by evening primrose oil and/or borage (starflower) oil‖, ―gamma-linolenic acid‖, ―evening primrose oil (Oenothera biennis) contains gamma-linolenic acid‖, ―borage oil (GLA= gamma linolenic acid)‖, ―oenothera biennis-evening primrose-seeds oil‖, ―long chain omega 6 polyunsaturated fatty acid GLA (gamma-linolenic acid)‖, ―Borago officinalis‖, and ―GLA (example from Borago officinalis, primrose oil, black currant seed oil)‖. In the context of the proposed health relationships, wordings, conditions of use and the clarifications provided by Member States, the Panel assumes that the food constituent that is the subject of the health claims is gamma-linolenic acid (GLA). The Panel considers that gamma-linolenic acid is sufficiently characterised.

Scientific Opinion on the substantiation of health claims related to gamma-linolenic acid (GLA) and maintenance of normal blood LDL-cholesterol concentrations (ID 2661, 4452, 4453), maintenance of normal blood pressure (ID 2662), reduction of menstrual discomfort (ID 495, 640, 1773, 1775), contribution to normal cognitive function (ID 1770), maintenance of the barrier function of the skin (ID 499, 591, 639, 676, 1554, 2003, 2065), “function of the cell membrane” (ID 1769), maintenance of normal structure, elasticity and appearance of the skin (ID 2660, 4296), and “anti-inflammatory properties” (ID 4454) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 / C.V. Agostoni, J.L. Bresson, S. Fairweather Tait, A. Flynn, I. Golly, H. Korhonen, P. Lagiou, M. Løvik, R. Marchelli, A. Martin, B. Moseley, M. Neuhäuser Berthold, H. Przyrembel, S. Salminen, Y. Sanz, S. Strain, S. Strobel, I. Tetens, D. Tomé, H. van Loveren, H. Verhagen. - In: EFSA JOURNAL. - ISSN 1831-4732. - 9:4(2011 Apr). [10.2903/j.efsa.2011.2059]

Scientific Opinion on the substantiation of health claims related to gamma-linolenic acid (GLA) and maintenance of normal blood LDL-cholesterol concentrations (ID 2661, 4452, 4453), maintenance of normal blood pressure (ID 2662), reduction of menstrual discomfort (ID 495, 640, 1773, 1775), contribution to normal cognitive function (ID 1770), maintenance of the barrier function of the skin (ID 499, 591, 639, 676, 1554, 2003, 2065), “function of the cell membrane” (ID 1769), maintenance of normal structure, elasticity and appearance of the skin (ID 2660, 4296), and “anti-inflammatory properties” (ID 4454) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

C.V. Agostoni
Primo
;
2011

Abstract

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims in relation to gamma-linolenic acid and maintenance of normal blood LDL-cholesterol concentrations, maintenance of normal blood pressure, reduction of menstrual discomfort, contribution to normal cognitive function, maintenance of the barrier function of the skin, ―function of the cell membrane‖, maintenance of normal structure, elasticity and appearance of the skin, and ―anti-inflammatory properties‖. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders. The food constituents that are the subject of the health claims are ―gamma-linolenic acid (GLA; C18: 3n-6) provided by evening primrose oil and/or borage (starflower) oil‖, ―gamma-linolenic acid‖, ―evening primrose oil (Oenothera biennis) contains gamma-linolenic acid‖, ―borage oil (GLA= gamma linolenic acid)‖, ―oenothera biennis-evening primrose-seeds oil‖, ―long chain omega 6 polyunsaturated fatty acid GLA (gamma-linolenic acid)‖, ―Borago officinalis‖, and ―GLA (example from Borago officinalis, primrose oil, black currant seed oil)‖. In the context of the proposed health relationships, wordings, conditions of use and the clarifications provided by Member States, the Panel assumes that the food constituent that is the subject of the health claims is gamma-linolenic acid (GLA). The Panel considers that gamma-linolenic acid is sufficiently characterised.
Gamma-linolenic acid ; GLA ; blood LDL-cholesterol ; blood pressure ; menstrual discomfort ; cell membrane ; skin ; inflammation ; health claims
Settore MED/49 - Scienze Tecniche Dietetiche Applicate
apr-2011
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/174538
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? ND
social impact